BioCentury | Nov 25, 2020
Product Development

Data Byte: a snapshot of the clinical cutaneous T cell lymphoma pipeline

...Histone deacetylaseHsp90 – Heat shock protein 90 IL-2 – Interleukin-2 IL-9 – Interleukin-9IL-12 – Interleukin-12KIR3DL2 (CD158K) – Killer cell immunoglobulin-like receptor three domains long cytoplasmic tail 2 MicroRNA-155...
BioCentury | Oct 17, 2019
Financial News

Innate gains dual listing, tops off fund-raise with private placement

...advance its three clinical oncology candidates: monalizumab, a mAb against NK cell checkpoint protein NKG2A; anti-KIR3DL2...
...Targets: C5AR1 (C5AR; CD88) - Complement receptor 5A; CD73 (NT5E) - Ecto-5’-nucleotidase; KIR3DL2 (CD158K) - Killer cell immunoglobulin-like receptor three domains long cytoplasmic tail 2...
...2201, IPH22XX) IPH4102 IPH5401 Innate Pharma S.A. CD22 Killer cell lectin-like receptor subfamily C member 1 (NKG2A) (CD159a) (KLRC1) Killer cell immunoglobulin-like receptor three domains long cytoplasmic tail 2 (KIR3DL2) (CD158K) Ecto-5'-nucleotidase...
BioCentury | Jun 8, 2018
Tools & Techniques

NK cell check-in

...member 1 (NKG2A; CD159a; KLRC1) Ph II Innate Pharma S.A. (Euronext:IPH) IPH4102 Antibody Killer cell immunoglobulin-like receptor three domains long cytoplasmic tail 2 (KIR3DL2; CD158K...
BioCentury | Dec 1, 2017
Clinical News

Innate sees no development path for lirilumab combo therapies

Innate Pharma S.A. (Euronext:IPH) said efficacy data from a Phase I/II trial of lirilumab (BMS-986015, IPH2102) in combination with Opdivo nivolumab to treat head and neck cancers "did not provide clear evidence of benefit to...
BioCentury | Nov 30, 2017
Clinical News

Innate reports additional Phase I data for IPH4102 in cutaneous T cell lymphoma (CTCL)

...IPH4102-101 trial. Among 20 patients with relapsed or refractory Sezary syndrome who were killer cell immunoglobulin-like receptor three domains long cytoplasmic tail 2 (KIR3DL2; CD158K)-positive...
...Marseille, France Product: IPH4102 Business: Cancer Molecular target: Killer cell immunoglobulin-like receptor three domains long cytoplasmic tail 2 (KIR3DL2; CD158K) Description: Humanized mAb against KIR3DL2...
...response and progression-free survival (PFS) Status: Phase I data Milestone: NA Claire Quang IPH4102 Innate Pharma S.A. Killer cell immunoglobulin-like receptor three domains long cytoplasmic tail 2 (KIR3DL2) (CD158K...
BioCentury | Feb 10, 2017
Clinical News

Lirilumab: Ph II EffiKIR data

Top-line data from the double-blind, French Phase II EffiKIR trial in about 150 elderly AML patients in first complete remission showed that maintenance treatment with 0.1 mg/kg lirilumab every 3 months and 1 mg/kg lirilumab...
BioCentury | Feb 6, 2017
Clinical News

Innate's lirilumab fails Phase II AML trial

Innate Pharma S.A. (Euronext:IPH) lost EUR 2.05 (16%) to EUR 11.05 on Monday after it said lirilumab ( IPH2102 ) missed the primary endpoint in the Phase II EffiKIR trial to treat elderly patients with acute myelogenous...
BioCentury | Nov 11, 2016
Clinical News

Lirilumab: Ph I/II CA223-001 data

Data from a cohort of 29 evaluable patients with advanced platinum-refractory squamous cell carcinoma of the head and neck (SCCHN) in the open-label, dose-escalation, international Phase I/II CA223-001 trial showed that IV lirilumab every 4...
BioCentury | Nov 4, 2016
Clinical News

IPH4102: Preliminary Ph I data

...Preliminary data from 16 evaluable patients with KIR3dL2-positive, relapsed or refractory CTCL in the dose-escalation portion...
...Product: IPH4102 Business: Cancer Molecular target: Killer cell immunoglobulin-like receptor three domains long cytoplasmic tail 2 ( KIR3dL2 ; CD158K) Description: Humanized mAb against KIR3dL2...
...PFS) Status: Preliminary Phase I data Milestone: Complete Phase I (2Q17) Julian Zhu IPH4102 Innate Pharma S.A. Killer cell immunoglobulin-like receptor three domains long cytoplasmic tail 2 (KIR3DL2) (CD158K...
BioCentury | Oct 10, 2016
Clinical News

Lirilumab: Phase II ongoing

A DSMB recommended for the seventh time continuation of the double-blind, placebo-controlled, French Phase II EffiKIR trial evaluating 0.1 and 1 mg/kg lirilumab based on a safety analysis. The trial completed enrollment of about 150...
Items per page:
1 - 10 of 26